Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Terminated
50 enrolled
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
iinnovate-1
Phase 1/2 Terminated
272 enrolled 67 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
RE-NEZ-SENS
Phase NA Terminated
5 enrolled
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
146 enrolled
AlloRelapseMM
Phase 3 Terminated
28 enrolled
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Phase 1 Terminated
56 enrolled
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
CARTIFAN-1
Phase 2 Terminated
123 enrolled
DC15-MM-01
Phase 1 Terminated
4 enrolled
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Phase 1 Terminated
6 enrolled
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
23 enrolled
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase 1 Terminated
37 enrolled
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
174 enrolled
AMBROBiMM
Terminated
3 enrolled
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
Phase NA Terminated
21 enrolled
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
24 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
5 enrolled
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Phase 1/2 Terminated
32 enrolled
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1 Terminated
96 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled 12 charts
FRE
Terminated
105 enrolled
Corneal Findings in Patients Treated With Belantamab Mafodotin
Terminated
12 enrolled
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
36 enrolled 17 charts
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
183 enrolled
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
10 enrolled 14 charts
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Phase 2 Terminated
88 enrolled 21 charts
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Phase 2 Terminated
15 enrolled 12 charts
Blood Samples to Identify Biomarkers of Busulfan
Terminated
139 enrolled
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Phase 1/2 Terminated
4 enrolled 16 charts
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Phase 2 Terminated
1 enrolled 14 charts
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Terminated
4,253 enrolled 21 charts
IFM2014-01
Phase 2 Terminated
26 enrolled
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Phase 1/2 Terminated
14 enrolled
Multiple Myeloma Patient Registry
Terminated
85 enrolled